Canada

There are several biologic drugs approved for use in Canada comprising an estimated 14-16 per cent of the prescription pharmaceutical market.

Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement. Canada’s 1994 NAFTA

The most thought-provoking book I read during my winter vacation this year was Salt Sugar Fat: How the Food Giants Hooked Us by Michael Moss.

In an industry where one out of 10,000 drugs makes it to market, and where many drugs fail after millions of dollars of investment, one of the challenges is to create an environment that enhances the chance of success and mitigates the high cost of failures.

The Quebec government recently announced, as part of its budget, the intended abolishment of the rule known as "BAP-15."

By a decision of Justice Zinn dated April 30, 2013, the Federal Court quashed a Board’s decision on excessive pricing of Copaxone.

Effective July 1, 2010 important changes to the rules governing the sale of drugs in Ontario will come into force.

After a decade-long battle, Health Canada has announced its intention to get out of the business of supplying medicinal marijuana to Canadians.

On April 26, 2013, Health Canada published a notice to inform clinical trial sponsors that information about Clinical Trial Applications ("CTAs") will be published.

In January 2012, the Minister of Health and Long-Term Care, Deb Matthews (the "Minister"), released Ontario’s Action Plan to Transform Health Care (the "Action Plan").

On August 27th, 2010, the City of Toronto enacted Zoning By-law 1156-2010, more commonly known as the new City of Toronto Harmonized Zoning By-law (the "New By-law").

In the recent decision, the British Columbia Court of Appeal addressed the issue of liability on the part of a Canadian government regulator for damages arising out of negligent performance of its duties where the performance of those duties led to a recall of the plaintiff's product.

The List sets out drugs and classes of drugs that are divided based on medicinal ingredients for human and veterinary use.

Norton Rose Group’s head of pharmaceuticals and life sciences, Patrick Kierans (based in Toronto), together with partners Richard A. Wagner (Ottawa) and Mélanie Thill-Tayara (Paris), assess the recent response by Canadian generic manufacturers to proposed reform of intellectual property law in Canada.

Do you provide your professional medical services directly to a health care institution rather than through a corporation you control?

Schmeiser v. Monsanto is the Supreme Court of Canada’s most recent decision involving higher life forms. In this case, Monsanto alleged that Schmeiser, a farmer, had infringed its patent rights by reproducing canola seeds and plants that contained genes and cells covered by Monsanto’s patent claims, and by selling the harvested canola seeds.

2012The complex market and regulatory framework for the sale of drugs in Ontario has been clarified, to some extent, by the recent decision of the Ontario Court of Appeal.

Amgen recently started litigation against Teva over the biologic drug filgrastim (Court File No. T-989-12).

Following a summary trial at the end of 2011, on 15 June 2012 the Honourable Madam Justice Lynn Smith of the Supreme Court of British Columbia issued a landmark judgment in which she concluded that the Criminal Code provisions prohibiting physicianassisted dying violated sections 15 (right to equality) and 7 (right to life, liberty and security of the person) of the Canadian Charter of Rights and Freedoms and were thus invalid:

A discussion on the story that a Prof. Seralini at Caen University had proven that GMOs are "poison."